Deformable registration for quantifying longitudinal tumor changes during neoadjuvant chemotherapy

被引:26
|
作者
Ou, Yangming [1 ]
Weinstein, Susan P. [1 ]
Conant, Emily F. [1 ]
Englander, Sarah [1 ]
Da, Xiao [1 ]
Gaonkar, Bilwaj [1 ]
Hsieh, Meng-Kang [1 ]
Rosen, Mark [1 ]
DeMichele, Angela [1 ]
Davatzikos, Christos [1 ]
Kontos, Despina [1 ]
机构
[1] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
关键词
deformable image registration; breast cancer; longitudinal breast MRI; tumor changes; evaluation; treatment; FREE-FORM DEFORMATION; PRESERVING NONRIGID REGISTRATION; BREAST-CANCER HETEROGENEITY; IMAGE REGISTRATION; PATHOLOGICAL RESPONSE; MAMMOGRAM REGISTRATION; MR-IMAGES; VOLUME; PREDICTION; MODEL;
D O I
10.1002/mrm.25368
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PurposeTo evaluate DRAMMS, an attribute-based deformable registration algorithm, compared to other intensity-based algorithms, for longitudinal breast MRI registration, and to show its applicability in quantifying tumor changes over the course of neoadjuvant chemotherapy. MethodsBreast magnetic resonance images from 14 women undergoing neoadjuvant chemotherapy were analyzed. The accuracy of DRAMMS versus five intensity-based deformable registration methods was evaluated based on 2,380 landmarks independently annotated by two experts, for the entire image volume, different image subregions, and patient subgroups. The registration method with the smallest landmark error was used to quantify tumor changes, by calculating the Jacobian determinant maps of the registration deformation. ResultsDRAMMS had the smallest landmark errors (6.054.86 mm), followed by the intensity-based methods CC-FFD (8.07 +/- 3.86 mm), NMI-FFD (8.21 +/- 3.81 mm), SSD-FFD (9.46 +/- 4.55 mm), Demons (10.76 +/- 6.01 mm), and Diffeomorphic Demons (10.82 +/- 6.11 mm). Results show that registration accuracy also depends on tumor versus normal tissue regions and different patient subgroups. ConclusionsThe DRAMMS deformable registration method, driven by attribute-matching and mutual-saliency, can register longitudinal breast magnetic resonance images with a higher accuracy than several intensity-matching methods included in this article. As such, it could be valuable for more accurately quantifying heterogeneous tumor changes as a marker of response to treatment. Magn Reson Med 73:2343-2356, 2015. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:2343 / 2356
页数:14
相关论文
共 50 条
  • [41] A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response
    Li, Xia
    Dawant, Benoit M.
    Welch, E. Brian
    Chakravarthy, A. Bapsi
    Freehardt, Darla
    Mayer, Ingrid
    Kelley, Mark
    Meszoely, Ingrid
    Gore, John C.
    Yankeelov, Thomas E.
    MAGNETIC RESONANCE IMAGING, 2009, 27 (09) : 1258 - 1270
  • [42] Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes
    Humbert, O.
    Berriolo-Riedinger, A.
    Riedinger, J. M.
    Coudert, B.
    Arnould, L.
    Cochet, A.
    Loustalot, C.
    Fumoleau, P.
    Brunotte, F.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2572 - 2577
  • [43] Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer
    Lee, Hyun
    Lee, Miseon
    Seo, Jeong-Han
    Gong, Gyungyub
    Lee, Hee Jin
    ANTICANCER RESEARCH, 2020, 40 (04) : 1883 - 1890
  • [44] Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis
    Luengo-Gil, Gines
    Gonzalez-Billalabeitia, Enrique
    Chaves-Benito, Asuncion
    Garcia Martinez, Elena
    Garcia Garre, Elisa
    Vicente, Vicente
    Ayala de la Pena, Francisco
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) : 577 - 587
  • [46] Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
    Leslie R. Euceda
    Tonje H. Haukaas
    Guro F. Giskeødegård
    Riyas Vettukattil
    Jasper Engel
    Laxmi Silwal-Pandit
    Steinar Lundgren
    Elin Borgen
    Øystein Garred
    Geert Postma
    Lutgarde M. C. Buydens
    Anne-Lise Børresen-Dale
    Olav Engebraaten
    Tone F. Bathen
    Metabolomics, 2017, 13
  • [47] Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer
    Kaigorodova, Evgeniya V.
    Savelieva, Olga E.
    Tashireva, Liubov A.
    Tarabanovskaya, Natalia A.
    Simolina, Elena I.
    Denisov, Evgeny V.
    Slonimskaya, Elena M.
    Choynzonov, Evgeny L.
    Perelmuter, Vladimir M.
    MOLECULES, 2018, 23 (04):
  • [48] Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
    Dickler, M
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (10): : 498 - 499
  • [49] Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis
    Ginés Luengo-Gil
    Enrique González-Billalabeitia
    Asunción Chaves-Benito
    Elena García Martínez
    Elisa García Garre
    Vicente Vicente
    Francisco Ayala de la Peña
    Breast Cancer Research and Treatment, 2015, 151 : 577 - 587
  • [50] Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
    Euceda, Leslie R.
    Haukaas, Tonje H.
    Giskeodegard, Guro F.
    Vettukattil, Riyas
    Engel, Jasper
    Silwal-Pandit, Laxmi
    Lundgren, Steinar
    Borgen, Elin
    Garred, Oystein
    Postma, Geert
    Buydens, Lutgarde M. C.
    Borresen-Dale, Anne-Lise
    Engebraaten, Olav
    Bathen, Tone F.
    METABOLOMICS, 2017, 13 (04)